GSK will hold an exclusive option for each of these assets for potential clinical development. Flagship and its bioplatform companies are entitled to receive milestone payments of up to $720m on ...

Pharmaceutical giant GlaxoSmithKline (GSK) has lifted its long-term sales guidance as it hailed a strong drug pipeline. It ...

Walmart has updated its logo for the first time in 20 years — and shoppers are seriously stunned. The retailer describes the new look as “a comprehensive brand refresh that reflects its ...

The FDA approved GSK’s drug for a common type of urinary tract infection (UTI) in women and adolescent girls, one of five new approvals the British drugmaker has been expecting this year.

Haleon has announced that it is launching as an independent company 100% focused on consumer health, completing its demerger from GSK. The newly listed business is driven by its purpose to deliver ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud.You can reach Elaine on Signal at elaineywchen.70.

British drugmaker GSK is preparing for potential new U.S. tariffs on its medicines and can handle the challenge, the company’s leader said Wednesday. “I would say we’ve been preparing, we ...

Come Monday, GSK and consumer health unit Haleon will officially part ways, leaving the Big Pharma's biopharma and vaccines divisions to stand on their own. Will CEO Emma Walmsley reach for new M&A?

The new look GSK disclosed its latest quartertly financials early Wednesday, and CEO Emma Walmsley discusses the results in a video while providing a corporate update in the detailed announcement.

New GSK should grow quickly, thanks to blockbusters such as its shingles vaccine. The snag is that starting in 2027 Dolutegravir, the molecule found in four of the group’s best-selling HIV ...

Two new vaccines for respiratory syncytial virus, or RSV, are boosting sales of drugmakers GSK and Pfizer because hundreds of thousands of older adults have gotten immunized so far for the fall ...

GSK(LSE:GSK) is navigating a dynamic environment marked by both opportunities and challenges. Recent highlights include a robust 13% sales growth and strategic innovations in R&D, contrasted with ...